MENU

Can HeartBeam (BEAT) Stock Reach $4.00?

a wireless medical technology company, which focuses on the delivery of health information

A.I.Advisor
published price charts
A.I.Advisor
Nov 12, 2026

Can HeartBeam (BEAT) Stock Reach $4.00?

HeartBeam, Inc. (BEAT), a Santa Clara, California-based medical technology company developing cable-free, ambulatory electrocardiogram (ECG) solutions for cardiac monitoring outside a medical setting, trades near $0.41, roughly 90% below its 52-week high. The shares remain the subject of a small and increasingly stale set of analyst price targets. The central question is whether BEAT can climb back toward a $4.00 stock price target.

Key Takeaways

  • The central $4.00 target is the arithmetic mean of four identifiable analyst price targets — $2.00 from Maxim Group, $4.00 from B. Riley Securities, and $5.00 each from StoneX and Benchmark — across a wide $2.00-to-$5.00 range.
  • At the latest price near $0.41, reaching $4.00 requires roughly 875% upside, a very large move by any standard.
  • Most of these targets were set in spring and summer 2026, before the stock's sharp decline, and coverage is thin and inconsistent across data providers.
  • Supporting factors include an FDA-cleared ambulatory ECG platform, an extended funding runway, and a narrowing quarterly net loss.
  • Principal risks are pre-revenue, development-stage execution, recurring shareholder dilution, and the possibility of further target cuts.
  • For more on the company's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for a fuller picture.
  • Readers can also explore Trending AI Robots for AI-driven market monitoring and trade-idea discovery.

Analyst Price Targets and Consensus View

Four current, identifiable analyst price targets were reviewed. The low is $2.00 from Maxim Group, which initiated coverage with a Buy in July 2026. The high is $5.00, held by both StoneX (reiterated Buy in August 2026) and Benchmark (which lowered its target from $8 in May 2026). B. Riley Securities set a $4.00 target in March 2026. The arithmetic mean is $4.00, within a wide $2.00-to-$5.00 range.

The picture is unusually fragmented. H.C. Wainwright lowered its target to $2.50 in May 2026 and then downgraded the stock to Neutral in September 2026, effectively removing its price objective, while D. Boral Capital downgraded to Hold in April 2026. Some aggregators report an average closer to $3.50 based on a different, smaller subset of targets. Because most targets substantially predate the stock's collapse and have not yet "caught up" to it, they should be read as indicative rather than precise. Bullish analysts emphasize the long-term remote cardiac monitoring opportunity; cautious voices point to slower commercial traction and dilution.

Current Market Position and Path Toward the Target

The latest verified price is about $0.41, with a market capitalization near $23 million. Reaching the $4.00 central target would require a gain of roughly 875%, which is a very large move. HeartBeam remains development-stage and loss-making, with negative earnings per share (EPS). Its most recent quarterly results showed a net loss in the low-teens millions of dollars, narrowing modestly year-over-year, and the company completed an equity raise at $0.80 per share in 2026 to extend its funding runway. The 52-week range of $0.355 to $4.00 underscores both the depth of the decline and the fact that the stock has already traded at the target level within the past year.

What Could Support a Move Toward the Target

  • Product and regulatory milestones. The company's FDA-cleared, credit-card-sized ECG platform targets a large addressable market for remote and ambulatory cardiac monitoring.
  • Funding runway. Recent capital raises have extended the cash runway, supporting continued commercialization efforts.
  • Improving losses. A narrowing net loss suggests some operating expense discipline even before meaningful revenue.
  • Residual analyst support. Several Buy ratings remain in place, reflecting long-term optimism about the technology.

What Could Prevent the Target From Being Reached

  • Pre-revenue execution risk. Commercialization has ramped more slowly than analysts originally modeled, prompting repeated target reductions.
  • Dilution. Additional equity raises at low prices have weighed heavily on per-share value and analyst fair-value estimates.
  • Funding needs. As a development-stage company, continued cash burn may require further capital.
  • Further downgrades. H.C. Wainwright's move to Neutral and D. Boral Capital's Hold rating signal waning conviction, and stale targets could be cut again.
  • Micro-cap volatility. Thin coverage and modest liquidity magnify price swings in both directions.

Technical Levels and Market Structure

The technical backdrop is notably weak. The $4.00 central target coincides with the stock's 52-week high, a level that now functions as major resistance and a prior breakdown point. Support sits near the $0.355-to-$0.40 zone around the 52-week low, with psychological levels at $0.50 and $1.00 in between. The long-term trend remains firmly negative, and the stock would need to reclaim progressively higher levels with sustained volume before any credible recovery toward the target could unfold.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though the specific horizon for each BEAT report is not always disclosed and can vary. Investors should monitor upcoming quarterly results and guidance, any new or revised funding arrangements, FDA and commercial launch milestones, and analyst target revisions. Given the divergence between the share price and the remaining targets, fresh analyst commentary will be especially informative.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like BEAT, these signals can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual review. Explore AI Daily Buy/Sell Signals to see how automated analysis can complement your own research.

Final Assessment

The $4.00 central target is the average of four identifiable analyst price targets spanning $2.00 to $5.00, but it reflects a valuation framework established largely before HeartBeam's roughly 90% decline. The required move of about 875% is very large, and the stock's development-stage status, recurring dilution, and already-softening analyst sentiment present serious obstacles. On the other side, an FDA-cleared product, an extended funding runway, and a narrowing loss provide a foundation. Whether the target is reachable depends on tangible commercial traction and funding stability; no outcome is guaranteed, and the wide analyst range signals genuine disagreement about the company's trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

BEAT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAT has been loosely correlated with SNOW. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BEAT jumps, then SNOW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAT
1D Price
Change %
BEAT100%
-10.94%
SNOW - BEAT
37%
Loosely correlated
-5.13%
APPN - BEAT
33%
Poorly correlated
+1.61%
MNDY - BEAT
32%
Poorly correlated
+3.23%
ZS - BEAT
31%
Poorly correlated
-5.29%
CRM - BEAT
31%
Poorly correlated
-1.47%
More

Groups containing BEAT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAT
1D Price
Change %
BEAT100%
-10.94%
Services to the Health Industry
industry (41 stocks)
-1%
Poorly correlated
-3.31%
Health Services
industry (238 stocks)
-41%
Negatively correlated
-2.69%